CHIEF COMMERCIAL OFFICER · Travere Therapeutics, Inc. · Common Stock
Side
A
Value
—
Shares
14.0K
Price
—
Executed
Apr 13, 2026
Disclosed
Apr 15, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Apr 13 executedApr 15, 2026 disclosed
TVTX · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 10.6% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Heerma Peter filed this Form 4 reporting a grant or award of TVTX on Apr 13, 2026. It became public on Apr 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CHIEF COMMERCIAL OFFICER
Heerma Petercik:0001789617
Issuer
Travere Therapeutics, Inc.cik:0001438533
Revision history · 0
No field has changed since this record was first ingested.
